We are a clinical-stage biopharmaceutical company engaged in the development and commercialization of drugs to treat important ophthalmic disorders. Our lead drug candidate, preservative-free Nyxol® Eye Drops, is being developed for multiple front-of-the-eye indications, including night vision disturbances, reversal of pharmacologically-induced mydriasis, and presbyopia. Nyxol is an investigational 505(b)(2) drug candidate that has been dosed in over 150 subjects across 7 completed Phase 1 and 2 trials. Our second drug candidate, APX3330, is a novel oral small molecule targeting retina indications, initially with plans for Phase 2 in diabetic retinopathy and diabetic macular edema, and future indications may include wet age-related macular degeneration and retinal vein occlusion. APX3330 has been dosed twice-a-day in over 400 subjects across 11 Phase 1 and Phase 2 trials. As part of our strategy, we will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late stage development, regulatory, and commercialization in key global markets.